Many research studies have looked into periodontal disease biomarkers. The aim of this study was to assess salivary levels of human beta defensin 1 and 2 (hBD-1) and (hBD-2) in different periodontal condition. The Periodontal Screening & Recording (PSR) system, a modification of de Community Periodontal Index Treatment Needs (CPITN), was used to evaluate the periodontal treatment needs of 120 patients without any systemic disease. Salivary levels of hBD-1 and hBD-2 were determined by ELISA. Higher hBD-1 levels were detected in the saliva of patients with a PSR/CPITN index of 3 and 4 (7,363±2,837pg/ mL) and in those with a PSR/CPITN index of 1 and 2 (7,750±3,477pg/mL) when compared to patients without periodontal disease, with a PSR/CPITN index of 0 (5,644±2,747pg/ mL; P=0.013). As with hBD-1, hBD2 levels were also higher in the saliva of patients with a PSR/CPITN index of 3 and 4 (310±98pg/mL) and a PSR/CPITN index of 1 and 2 (318±85pg/mL) when compared to patients with a PSR/CPITN index of 0 (251±87pg/mL; P=0.011). In conclusion, compared to patients without periodontal disease, PSR/CPITN index 0, we verified higher salivary concentrations of hBD-1 and hBD-2 in patients with some degree of periodontal detected by PSR/CPITN between 1 and 4.